Similarly, TERT promoter mutations, which are highly prevalent in bladder cancer, are often clonal and present in both primary and metastatic lesions, suggesting their role in early tumorigenesis and potential utility as stable biomarkers for monitoring disease progression (Rachakonda et al., 2013). This evidence concerns the gene TERT and urinary bladder cancer.